Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Shares hit a record after the Danish pharmaceutical giant said the drug could be more effective than blockbuster Wegovy.

Novo Nordisk Surges After Early Trial Shows Promise of New Obesity Drug

Novo Nordisk stock jumped after the Danish giant said its experimental oral drug amycretin showed a 13.1% weight loss after 12 weeks in a phase 1 trial.

Novo Nordisk Jumps On Promising Results For New Weight-Loss Drug

Eli Lilly

Novo Nordisk shares climbed 5% on Thursday morning after the Danish pharmaceutical giant reported positive early trial data for a new weight loss drug.

Novo Nordisk shares jump 5% on promising weight loss trial results; Eli Lilly dips

Novo Nordisk will begin a Phase II trial of its highly anticipated experimental drug amycretin in the second half of the year with results due in early 2026, the company's head of research and development Martin Lange Holst said on Thursday.

Novo Nordisk to begin Phase II trial of experimental obesity drug amycretin in H2 2024

Novo Nordisk , maker of obesity drug Wegovy, on Thursday said it would present early-stage trial data for its highly anticipated pipeline drug, amycretin, for treatment of Type 2 diabetes.

Novo Nordisk to present early-stage trial data for new diabetes drug at investor meeting

Bagsværd, Denmark, 7 March 2024 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025.

Highlights to be presented at Novo Nordisk's Capital Markets Day 2024

Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.

Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success

A clinical trial of semaglutide studying its ability to prevent kidney disease-related events was published. The study met its primary endpoint, but many observers were expecting better results.

Why Novo Nordisk Stock Tumbled by Nearly 3% on Tuesday

ARM Holdings PLC

Arm Stock and Novo Nordisk stock topped this screen of leading global growth stocks. One of them is near a buy point.

U.S. Stocks Aren't The Only Game In Town: Arm, Novo Please Investors

Viking Therapeutics' weight loss candidate produced positive phase 2 results. The drug could eventually be a challenger to Novo Nordisk's Wegovy.

A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?

Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish drug giant hailed the headline results from its FLOW trial which reduced kidney disease progression, major adverse cardiovascular events and death by 24% compared to placebo.

Novo Nordisk reveals positive Ozempic kidney results

Eli Lilly and Novo Nordisk stock each rose over 50% in 2023 thanks to their diabetes treatments. Industry research suggests the diabetes market will continue to grow for decades to come.

Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why

The results add to the growing evidence that the highly popular injection has broader health benefits for patients beyond treating Type 2 diabetes.

Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial

Novo Nordisk A.S. said Tuesday a five-year trial of its Ozempic weight-loss drug helped reduce the risk of kidney disease-related events in people with Type 2 diabetes by 24%.

Novo Nordisk says Ozempic reduced risk of kidney problems by 24% in patients with Type 2 diabetes

Novo Nordisk shares falls after diabetic kidney results reported

United Therapeutics

Vertex Pharmaceuticals

The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment opportunities in 2024.

Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making

Novo Nordisk's blockbuster weight-loss drug cuts the risk of kidney disease-related events in diabetic patients by 24%, according to a new clinical trial conducted by the company.

Novo Nordisk Says Ozempic Drug Cuts Risk of Kidney Problems

Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, according to a large late-stage study.

Novo Nordisk Ozempic trial delays progression of chronic kidney disease

Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to efficacy, which was announced on 10 October 2023, based on a recommendation from an Independent Data Monitoring Committee. The double-blind trial compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care for prevention of progression of kidney impairment and risk of kidney and cardiovascular mortality in people with type 2 diabetes and chronic kidney disease (CKD). The trial enrolled 3,533 people with type 2 diabetes and CKD.

Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial

Blockbuster drugs can be disproportionately beneficial for biopharmas. Novo Nordisk is already squeezing a lot of cash out of semaglutide.

Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly

Viking Therapeutics wowed the market with its latest phase 2 data. Its weight loss drug candidate might be better than the competition.

Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.

Weightwatchers International Inc.

Yes, Oprah Winfrey is in the news again — in this case, for her decision to sell her stake in WW International WW, +8.33% (formerly known as WeightWatchers) and leave the company's board. The decision came after Winfrey announced, to considerable backlash, that she was taking a weight-loss drug to help her in her longtime battle to lose some pounds and keep them off, in addition to hiking, drinking plenty of water and other methods.

Can we cut Oprah Winfrey some slack? The struggle to lose weight is real — and drugs can be a lifesaver.

An analyst cranked his price target higher on the Danish pharmaceutical company. He increased it by 16%.

Why Novo Nordisk Stock Topped the Market Today

Intuitive Surgical

The Magnificent Seven are stealing the show this year on the market. They're all technology companies -- but there are opportunities elsewhere, too.

These 4 Stocks Are the "Magnificent Seven" of Healthcare

Apple

Amazon

ASML Hld

AstraZeneca

Alphabet

GlaxoSmithKline

L'Oreal SA

LVMH Moet Hennessy Louis Vuitton

Microsoft

Netflix

Nestle SA

NVIDIA

Novartis

Roche Holding AG

SAP SE

Sanofi

Tesla

Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.

‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?

News for Novo Nordisk Stock (NVO)